OBJECTIVES: The pharmacokinetics of azithromycin were evaluated in 12 healthy volunteers. METHODS: This was an open study in 12 healthy male subjects. Participants received a single dose of 2 x 250mg azithromycin (two azithromycin capsules) administered orally in the fasting state with 240ml water on three consecutive days. RESULTS: After oral intake of two capsules of 250mg azithromycin over three consecutive days (the normal treatment regimen in adults), azithromycin was present in measurable levels in plasma (>5 microg/L) for 7 to 17 days after the beginning of treatment. The apparent elimination half-life was very long (observed range: 49 to 108 hours, i.e. about 2 to 4.5 days). From the results in plasma, one can extrapolate that the azithromycin concentration would remain above 1 microg/L (corresponding to concentrations in tissues above 0.1 mg/L) for up to 15 to 30 days following treatment. The elimination half-life of azithromycin (average of 76 hours) was in agreement with values of depletion rates in tissues corresponding to a half-life of 60 to 72 hours. CONCLUSION: In conclusion, the utility of the long exposure of patients with benign respiratory infections to azithromycin and to subinhibitory concentrations of azithromycin should be questioned.
RCT Entities:
OBJECTIVES: The pharmacokinetics of azithromycin were evaluated in 12 healthy volunteers. METHODS: This was an open study in 12 healthy male subjects. Participants received a single dose of 2 x 250mg azithromycin (two azithromycin capsules) administered orally in the fasting state with 240ml water on three consecutive days. RESULTS: After oral intake of two capsules of 250mg azithromycin over three consecutive days (the normal treatment regimen in adults), azithromycin was present in measurable levels in plasma (>5 microg/L) for 7 to 17 days after the beginning of treatment. The apparent elimination half-life was very long (observed range: 49 to 108 hours, i.e. about 2 to 4.5 days). From the results in plasma, one can extrapolate that the azithromycin concentration would remain above 1 microg/L (corresponding to concentrations in tissues above 0.1 mg/L) for up to 15 to 30 days following treatment. The elimination half-life of azithromycin (average of 76 hours) was in agreement with values of depletion rates in tissues corresponding to a half-life of 60 to 72 hours. CONCLUSION: In conclusion, the utility of the long exposure of patients with benign respiratory infections to azithromycin and to subinhibitory concentrations of azithromycin should be questioned.
Authors: K M Olsen; G San Pedro; L P Gann; P O Gubbins; D M Halinski; G D Campbell Journal: Antimicrob Agents Chemother Date: 1996-11 Impact factor: 5.191
Authors: G Panteix; B Guillaumond; R Harf; A Desbos; V Sapin; M Leclercq; M Perrin-Fayolle Journal: J Antimicrob Chemother Date: 1993-06 Impact factor: 5.790
Authors: P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger Journal: Antimicrob Agents Chemother Date: 2013-01-28 Impact factor: 5.191
Authors: Melinda M Pettigrew; Brian T Tsuji; Janneane F Gent; Yong Kong; Patricia N Holden; Sanjay Sethi; Timothy F Murphy Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Lenka A Vodstrcil; Thusitha W T Rupasinghe; Fabian Y S Kong; Dedreia Tull; Karen Worthington; Marcus Y Chen; Wilhelmina M Huston; Peter Timms; Malcolm J McConville; Christopher K Fairley; Catriona S Bradshaw; Sepehr N Tabrizi; Jane S Hocking Journal: PLoS One Date: 2017-05-12 Impact factor: 3.240
Authors: Fabian Y S Kong; Thusitha W Rupasinghe; Julie A Simpson; Lenka A Vodstrcil; Christopher K Fairley; Malcolm J McConville; Jane S Hocking Journal: PLoS One Date: 2017-03-28 Impact factor: 3.240